Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .
Effect of a Single High Loading Dose of Rosuvastatin on Percutaneous Coronary Intervention for Acute Coronary Syndromes
Objectives : A high loading dose of atorvastatin has been confirmed to reduce postprocedural events in patients undergoing percutaneous coronary intervention ( PCI ) . In this study , we sought to investigate the protective effects of rosuvastatin in patients with acute coronary syndromes ( ACS ) undergoing PCI and to determine the effect of rosuvastatin pretreatment on the postprocedural levels of high-sensitivity C-reactive protein ( hs-CRP ) , interleukin 6 ( IL-6 ) , and monocyte chemotactic protein 1 ( MCP-1 ) . Methods : A total of 125 patients with non-ST-segment elevation ACS were r and omized to pretreatment with rosuvastatin ( 20 mg 2 - 4 hours before PCI [ n = 62 ] ) or placebo ( n = 63 ) . All the patients received subsequent long-term rosuvastatin treatment ( 10 mg/d ) . The main end point of the trial was the 30-day incidence of major adverse cardiac events ( death , myocardial infa rct ion , or unplanned revascularization ) . Plasma levels of hs-CRP , IL-6 , and MCP-1 were detected before PCI and 6 hours , 24 hours , and 3 days after PCI . Results : The primary end point occurred in 8.1 % of the patients in the rosuvastatin arm and 22.2 % in the placebo arm ( P < .01 ) ; this difference was entirely attributed to a reduced incidence of myocardial infa rct ion ( 8.1 % vs 22.2 % ; P < .01 ) . The postprocedural elevation in creatine kinase-MB and troponin I was also significantly lower in the rosuvastatin group at 6 hours , 24 hours , and 3 days . Plasma levels of hs-CRP , IL-6 , and MCP-1 increased significantly after PCI in both the rosuvastatin and control groups ; however , the postprocedural elevations in hs-CRP and IL-6 levels were significantly lower in the rosuvastatin group than the control group . Conclusions : A single , high dose ( 20 mg ) of rosuvastatin prior to PCI reduces postprocedural myocardial injury in patients with ACS , with a concomitant attenuation of the postprocedural increase in hs-CRP and IL-6 levels
Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .